Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2013

Open Access 01-12-2013 | Review

Galectin-3: its role in asthma and potential as an anti-inflammatory target

Authors: Peng Gao, Jodie L Simpson, Jie Zhang, Peter G Gibson

Published in: Respiratory Research | Issue 1/2013

Login to get access

Abstract

Galectins constitute an evolutionary conserved family that bind to β-galactosides. Increasing evidence shows that galectins are involved in many fundamental biological processes such as cellular communication, inflammation, differentiation and apoptosis. Changes in galectin-3 (Gal-3) expression are commonly seen in cancer and pre-cancerous conditions, and Gal-3 may be involved in the regulation of diverse cancer cell activities that contribute to tumourigenesis, cancer progression and metastasis. In addition, Gal-3 is a pro-inflammatory regulator in rheumatoid arthritis. Gal-3 has been shown to be involved in many aspects in allergic inflammation, such as eosinophil recruitment, airway remodeling, development of a Th2 phenotype as well as increased expression of inflammatory mediators. In an in vivo model it was shown that bronchoalveolar lavage (BAL) fluid from ovalbumin-challenged mice contained significantly higher levels of Gal-3 compared to control mice. The molecular mechanisms of Gal-3 in human asthma have not been fully elucidated. This review will focus on what is known about the Gal-3 and its role in the pathophysiological mechanisms of asthma to evaluate the potential of Gal-3 as a biomarker and therapeutic target of asthma.
Appendix
Available only for authorised users
Literature
1.
Cooper DN: Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002, 1572: 209-231. 10.1016/S0304-4165(02)00310-0.PubMed
2.
Vasta GR, Quesenberry M, Ahmed H, O’Leary N: C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Dev Comp Immunol. 1999, 23: 401-420. 10.1016/S0145-305X(99)00020-8.PubMed
3.
Vasta GR: Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol. 2012, 946: 21-36. 10.1007/978-1-4614-0106-3_2.PubMedPubMedCentral
4.
Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F: Introduction to galectins. Glycoconj J. 2004, 19: 433-440.PubMed
5.
Yang RY, Rabinovich GA, Liu FT: Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008, 10: e17-PubMed
6.
Sato S, Nieminen J: Seeing strangers or announcing “danger”: galectin-3 in two models of innate immunity. Glycoconj J. 2004, 19: 583-591.PubMed
7.
8.
Rabinovich GA: Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ. 1999, 6: 711-721. 10.1038/sj.cdd.4400535.PubMed
9.
Di Lella S, Sundblad V, Cerliani JP, Guardia CM, Estrin DA, Vasta GR, Rabinovich GA: When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry. 2011, 50: 7842-7857. 10.1021/bi201121m.PubMedPubMedCentral
10.
Cooper DN, Barondes SH: God must love galectins; he made so many of them. Glycobiology. 1999, 9: 979-984. 10.1093/glycob/9.10.979.PubMed
11.
Liu FT: Galectins: a new family of regulators of inflammation. Clin Immunol. 2000, 97: 79-88. 10.1006/clim.2000.4912.PubMed
12.
Cummings RD, Liu FT: Galectins. Essentials of Glycobiology. Edited by: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. 2009, La Jolla, California: Cold Spring Harbor NY: The Consortium of Glycobiology Editors
13.
Rabinovich GA, Toscano MA: Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009, 9: 338-352. 10.1038/nri2536.PubMed
14.
Ho MK, Springer TA: Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol. 1982, 128: 1221-1228.PubMed
15.
Rabinovich GA, Toscano MA, Jackson SS, Vasta GR: Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol. 2007, 17: 513-520. 10.1016/j.sbi.2007.09.002.PubMedPubMedCentral
16.
Brewer CF, Miceli MC, Baum LG: Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol. 2002, 12: 616-623. 10.1016/S0959-440X(02)00364-0.PubMed
17.
Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW: Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004, 306: 120-124. 10.1126/science.1102109.PubMed
18.
Liu FT, Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer. 2005, 5: 29-41. 10.1038/nrc1527.PubMed
19.
Elad-Sfadia G, Haklai R, Balan E, Kloog Y: Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem. 2004, 279: 34922-34930. 10.1074/jbc.M312697200.PubMed
20.
Menon RP, Strom M, Hughes RC: Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner. FEBS Lett. 2000, 470: 227-231. 10.1016/S0014-5793(00)01310-7.PubMed
21.
Paron I, Scaloni A, Pines A, Bachi A, Liu FT, Puppin C, Pandolfi M, Ledda L, Di Loreto C, Damante G, Tell G: Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun. 2003, 302: 545-553. 10.1016/S0006-291X(03)00151-7.PubMed
22.
Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H, Raz A: Implication of galectin-3 in Wnt signaling. Cancer Res. 2005, 65: 3535-3537. 10.1158/0008-5472.CAN-05-0104.PubMed
23.
Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A: Galectin-3, a novel binding partner of beta-catenin. Cancer Res. 2004, 64: 6363-6367. 10.1158/0008-5472.CAN-04-1816.PubMed
24.
Zuberi RI, Hsu DK, Kalayci O, Chen HY, Sheldon HK, Yu L, Apgar JR, Kawakami T, Lilly CM, Liu FT: Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol. 2004, 165: 2045-2053. 10.1016/S0002-9440(10)63255-5.PubMedPubMedCentral
25.
Saegusa J, Hsu DK, Chen HY, Yu L, Fermin A, Fung MA, Liu FT: Galectin-3 is critical for the development of the allergic inflammatory response in a mouse model of atopic dermatitis. Am J Pathol. 2009, 174: 922-931. 10.2353/ajpath.2009.080500.PubMedPubMedCentral
26.
Ge XN, Bahaie NS, Kang BN, Hosseinkhani MR, Ha SG, Frenzel EM, Liu FT, Rao SP, Sriramarao P: Allergen-induced airway remodeling is impaired in galectin-3-deficient mice. J Immunol. 2010, 185: 1205-1214. 10.4049/jimmunol.1000039.PubMedPubMedCentral
27.
Lok DJ, Lok SI, de la Porte Bruggink-Andre PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P: Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013, 102: 103-110. 10.1007/s00392-012-0500-y.PubMed
28.
Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, Michel BA, Gay RE, Liu FT, Gay S, Neidhart M: Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2788-2795. 10.1002/art.11287.PubMed
29.
Ezzat MH, El-Gammasy TM, Shaheen KY, Osman AO: Elevated production of galectin-3 is correlated with juvenile idiopathic arthritis disease activity, severity, and progression. Int J Rheum Dis. 2011, 14: 345-352. 10.1111/j.1756-185X.2011.01632.x.PubMed
30.
Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, Lee EB, Song YW: Serum galectin-3 and galectin-3 binding protein levels in Behcet’s disease and their association with disease activity. Clin Exp Rheumatol. 2007, 25: S41-S45.PubMed
31.
Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S: Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000, 6: 1389-1393.PubMed
32.
Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S, Altomare DF: Serum levels of galectin-3 and its ligand 90 k/mac-2 bp in colorectal cancer patients. Immunopharmacol Immunotoxicol. 2010, 32: 160-164. 10.3109/08923970902936880.PubMed
33.
Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO: Serum level of galectin-3 in human bladder cancer. J Med Invest. 2008, 55: 127-132. 10.2152/jmi.55.127.PubMed
34.
Busse WW, Lemanske RF: Asthma. N Engl J Med. 2001, 344: 350-362. 10.1056/NEJM200102013440507.PubMed
35.
Gritzmacher CA, Robertson MW, Liu FT: IgE-binding protein. Subcellular location and gene expression in many murine tissues and cells. J Immunol. 1988, 141: 2801-2806.PubMed
36.
Liu FT, Patterson RJ, Wang JL: Intracellular functions of galectins. Biochim Biophys Acta. 2002, 1572: 263-273. 10.1016/S0304-4165(02)00313-6.PubMed
37.
Farnworth SL, Henderson NC, Mackinnon AC, Atkinson KM, Wilkinson T, Dhaliwal K, Hayashi K, Simpson AJ, Rossi AG, Haslett C, Sethi T: Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function. Am J Pathol. 2008, 172: 395-405. 10.2353/ajpath.2008.070870.PubMedPubMedCentral
38.
Mok SW, Riemer C, Madela K, Hsu DK, Liu FT, Gultner S, Heise I, Baier M: Role of galectin-3 in prion infections of the CNS. Biochem Biophys Res Commun. 2007, 359: 672-678. 10.1016/j.bbrc.2007.05.163.PubMed
39.
Sanchez-Cuellar S, De la Fuente H, Cruz-Adalia A, Lamana A, Cibrian D, Giron RM, Vara A, Sanchez-Madrid F, Ancochea J: Reduced expression of galectin-1 and galectin-9 by leucocytes in asthma patients. Clin Exp Immunol. 2012, 170: 365-374. 10.1111/j.1365-2249.2012.04665.x.PubMedPubMedCentral
40.
Darrow AL, Shohet RV, Maresh JG: Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiol Genomics. 2011, 43: 1144-1152. 10.1152/physiolgenomics.00035.2011.PubMedPubMedCentral
41.
Nieminen J, St-Pierre C, Bhaumik P, Poirier F, Sato S: Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol. 2008, 180: 2466-2473.PubMed
42.
Deo P, Glenn JV, Powell LA, Stitt AW, Ames JM: Upregulation of oxidative stress markers in human microvascular endothelial cells by complexes of serum albumin and digestion products of glycated casein. J Biochem Mol Toxicol. 2009, 23: 364-372. 10.1002/jbt.20301.PubMed
43.
Gil CD, La M, Perretti M, Oliani SM: Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int. 2006, 30: 338-344. 10.1016/j.cellbi.2005.12.010.PubMed
44.
Rao SP, Wang Z, Zuberi RI, Sikora L, Bahaie NS, Zuraw BL, Liu FT, Sriramarao P: Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J Immunol. 2007, 179: 7800-7807.PubMed
45.
Yang RY, Hsu DK, Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996, 93: 6737-6742. 10.1073/pnas.93.13.6737.PubMedPubMedCentral
46.
Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S, Raz A: CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003, 63: 8302-8311.PubMed
47.
Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S: Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. Trends Immunol. 2002, 23: 313-320. 10.1016/S1471-4906(02)02232-9.PubMed
48.
Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR: Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol. 2001, 159: 1055-1060. 10.1016/S0002-9440(10)61780-4.PubMedPubMedCentral
49.
Yu F, Finley RL, Raz A, Kim HR: Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002, 277: 15819-15827. 10.1074/jbc.M200154200.PubMed
50.
Matarrese P, Tinari N, Semeraro ML, Natoli C, Iacobelli S, Malorni W: Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett. 2000, 473: 311-315. 10.1016/S0014-5793(00)01547-7.PubMed
51.
Dumic J, Dabelic S, Flogel M: Galectin-3: an open-ended story. Biochim Biophys Acta. 2006, 1760: 616-635. 10.1016/j.bbagen.2005.12.020.PubMed
52.
Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M, Liu FT: Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol. 2000, 165: 2156-2164.PubMed
53.
Yoon J, Terada A, Kita H: CD66b regulates adhesion and activation of human eosinophils. J Immunol. 2007, 179: 8454-8462.PubMed
54.
Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, Liu FT: Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000, 156: 1073-1083. 10.1016/S0002-9440(10)64975-9.PubMedPubMedCentral
55.
Colnot C, Ripoche MA, Milon G, Montagutelli X, Crocker PR, Poirier F: Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology. 1998, 94: 290-296. 10.1046/j.1365-2567.1998.00517.x.PubMedPubMedCentral
56.
Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR: Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol. 1995, 147: 1016-1028.PubMedPubMedCentral
57.
Karlsson A, Christenson K, Matlak M, Bjorstad A, Brown KL, Telemo E, Salomonsson E, Leffler H, Bylund J: Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009, 19: 16-20.PubMed
58.
Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT: Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest. 2003, 112: 389-397.PubMedPubMedCentral
59.
Nair MG, Cochrane DW, Allen JE: Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol Lett. 2003, 85: 173-180. 10.1016/S0165-2478(02)00225-0.PubMed
60.
Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, Bogaert P, Boonefaes T, et al: Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol. 2005, 77: 321-327.PubMed
61.
62.
Li Y, Komai-Koma M, Gilchrist DS, Hsu DK, Liu FT, Springall T, Xu D: Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J Immunol. 2008, 181: 2781-2789.PubMed
63.
Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, Liu FT, Chammas R, Roque-Barreira MC: Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol. 2006, 168: 1910-1920. 10.2353/ajpath.2006.050636.PubMedPubMedCentral
64.
MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T: Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008, 180: 2650-2658.PubMed
65.
Cumpstey I, Sundin A, Leffler H, Nilsson UJ: C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. Angew Chem Int Ed Engl. 2005, 44: 5110-5112. 10.1002/anie.200500627.PubMed
66.
Kuwabara I, Liu FT: Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol. 1996, 156: 3939-3944.PubMed
67.
Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG: Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol. 2002, 168: 1813-1822.PubMed
68.
Schroder AK, Uciechowski P, Fleischer D, Rink L: Crosslinking of CD66B on peripheral blood neutrophils mediates the release of interleukin-8 from intracellular storage. Hum Immunol. 2006, 67: 676-682. 10.1016/j.humimm.2006.05.004.PubMed
69.
Colnot C, Fowlis D, Ripoche MA, Bouchaert I, Poirier F: Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn. 1998, 211: 306-313. 10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L.PubMed
70.
Feuk-Lagerstedt E, Jordan ET, Leffler H, Dahlgren C, Karlsson A: Identification of CD66a and CD66b as the major galectin-3 receptor candidates in human neutrophils. J Immunol. 1999, 163: 5592-5598.PubMed
71.
Nieminen J, Kuno A, Hirabayashi J, Sato S: Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem. 2007, 282: 1374-1383.PubMed
72.
Yamaoka A, Kuwabara I, Frigeri LG, Liu FT: A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol. 1995, 154: 3479-3487.PubMed
73.
Nieminen J, St-Pierre C, Sato S: Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J Leukoc Biol. 2005, 78: 1127-1135.PubMed
74.
Fernandez GC, Ilarregui JM, Rubel CJ, Toscano MA, Gomez SA, Beigier Bompadre M, Isturiz MA, Rabinovich GA, Palermo MS: Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology. 2005, 15: 519-527.PubMed
75.
Del Pozo V, Rojo M, Rubio ML, Cortegano I, Cardaba B, Gallardo S, Ortega M, Civantos E, Lopez E, Martin-Mosquero C, et al: Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation. Am J Respir Crit Care Med. 2002, 166: 732-737. 10.1164/rccm.2111031.PubMed
76.
Lopez E, Del Pozo V, Miguel T, Sastre B, Seoane C, Civantos E, Llanes E, Baeza ML, Palomino P, Cardaba B, et al: Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol. 2006, 176: 1943-1950.PubMed
77.
Lopez E, Zafra MP, Sastre B, Gamez C, Lahoz C, Del Pozo V: Gene expression profiling in lungs of chronic asthmatic mice treated with galectin-3: downregulation of inflammatory and regulatory genes. Mediators Inflamm. 2011, 2011: 823279-PubMedPubMedCentral
78.
Frigeri LG, Zuberi RI, Liu FT: Epsilon BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells. Biochemistry. 1993, 32: 7644-7649. 10.1021/bi00081a007.PubMed
79.
Zuberi RI, Frigeri LG, Liu FT: Activation of rat basophilic leukemia cells by epsilon BP, an IgE-binding endogenous lectin. Cell Immunol. 1994, 156: 1-12. 10.1006/cimm.1994.1148.PubMed
80.
Suzuki Y, Inoue T, Yoshimaru T, Ra C: Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition. Biochim Biophys Acta. 2008, 1783: 924-934. 10.1016/j.bbamcr.2008.01.025.PubMed
81.
Chen HY, Sharma BB, Yu L, Zuberi R, Weng IC, Kawakami Y, Kawakami T, Hsu DK, Liu FT: Role of galectin-3 in mast cell functions: galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression. J Immunol. 2006, 177: 4991-4997.PubMed
82.
Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, Von Bernstorff W, Eberlein TJ: Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol. 2001, 69: 555-564.PubMed
83.
Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, Baum LG: Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol. 2006, 176: 778-789.PubMed
84.
Arencibia I, Frankel G, Sundqvist KG: Induction of cell death in T lymphocytes by invasin via beta1-integrin. Eur J Immunol. 2002, 32: 1129-1138. 10.1002/1521-4141(200204)32:4<1129::AID-IMMU1129>3.0.CO;2-G.PubMed
85.
Brown TJ, Shuford WW, Wang WC, Nadler SG, Bailey TS, Marquardt H, Mittler RS: Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells. J Biol Chem. 1996, 271: 27686-27695. 10.1074/jbc.271.44.27686.PubMed
86.
Lesage S, Steff AM, Philippoussis F, Page M, Trop S, Mateo V, Hugo P: CD4+ CD8+ thymocytes are preferentially induced to die following CD45 cross-linking, through a novel apoptotic pathway. J Immunol. 1997, 159: 4762-4771.PubMed
87.
Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, Bazarbachi A, Benhamou M, Monteiro RC, Hermine O: A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood. 2004, 103: 1838-1845. 10.1182/blood-2003-07-2440.PubMed
88.
Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML: An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 2002, 99: 10706-10711. 10.1073/pnas.162362999.PubMedPubMedCentral
89.
Wills-Karp M: Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999, 17: 255-281. 10.1146/annurev.immunol.17.1.255.PubMed
90.
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, et al: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008, 31: 143-178. 10.1183/09031936.00138707.PubMed
91.
Simpson JL, Scott R, Boyle MJ, Gibson PG: Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006, 11: 54-61. 10.1111/j.1440-1843.2006.00784.x.PubMed
92.
Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003, 167: 1655-1659. 10.1164/rccm.200206-525OC.PubMed
93.
Leckie MJ, Ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000, 356: 2144-2148. 10.1016/S0140-6736(00)03496-6.PubMed
94.
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007, 176: 1062-1071. 10.1164/rccm.200701-085OC.PubMed
95.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009, 360: 973-984. 10.1056/NEJMoa0808991.PubMedPubMedCentral
96.
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O’Byrne PM: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009, 360: 985-993. 10.1056/NEJMoa0805435.PubMed
97.
Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL: A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010, 181: 788-796. 10.1164/rccm.200909-1448OC.PubMed
98.
Barnes PJ: Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008, 8: 183-192. 10.1038/nri2254.PubMed
99.
Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV: T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009, 180: 388-395. 10.1164/rccm.200903-0392OC.PubMedPubMedCentral
100.
Dos Santos G, Kutuzov MA, Ridge KM: The inflammasome in lung diseases. Am J Physiol Lung Cell Mol Physiol. 2012, 303: L627-L633. 10.1152/ajplung.00225.2012.PubMed
101.
Mortaz E, Masjedi MR, Allameh A, Adcock IM: Inflammasome signaling in pathogenesis of lung diseases. Curr Pharm Des. 2012, 18: 2320-2328. 10.2174/138161212800166077.PubMed
Metadata
Title
Galectin-3: its role in asthma and potential as an anti-inflammatory target
Authors
Peng Gao
Jodie L Simpson
Jie Zhang
Peter G Gibson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2013
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-14-136

Other articles of this Issue 1/2013

Respiratory Research 1/2013 Go to the issue

Review

Improving physical activity in COPD: towards a new paradigm

Research

Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease

Research

Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension

Research

Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts

Research

Conditional over-expression of RAGE by embryonic alveolar epithelium compromises the respiratory membrane and impairs endothelial cell differentiation

Letter to the Editor

Interleukin-6 and statin therapy: potential role in the management of COPD
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits